Union Budget 2026 boosts India’s biopharma ambitions: USAIC

USAIC commended the Finance Minister and the Government of India for what it described as decisive measures across strategic sectors.

USAIC President, Karun Rishi / USAIC

The annual Union Budget sends a clear policy signal on biopharma and healthcare innovation, the USA India Chambers of Commerce (USAIC) said, citing new investments, expansion of clinical trial infrastructure, and steps toward global regulatory alignment.

The government’s early focus on biopharma, including the Biopharma Shakti initiative and the plan to create 1,000 clinical trial sites nationwide, reflected a decisive push to move India up the global value chain in biopharma and healthcare innovation, USAIC president Karun Rishi told IANS.

ALSO READ: U.S. trade bodies hail India’s growth-focused Budget

This post is for paying subscribers only

SUBSCRIBE NOW

Comments

This is a Premium Article, available exclusively to our subscribers.

Read 500+ such News or articles every month by subscribing today!
Monthly

Free

Limited Access

Limited View

Free weekly E-Paper

Subscribe Now
Monthly

$10

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Annual

$50

Full Access

Unlimited View

Free weekly E-Paper

Free daily newsletter

Subscribe Now
Start the conversation

Become a member of New India Abroad to start commenting.

Sign Up Now

Already have an account? Login